Study detail
Recruiting
Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Contemporary Patients With Metastatic Castration-Resistant Prostate Cancer in the PRECISION Data Platform
Novartis Pharmaceuticals
Summary
The aim of this study is to assess treatment patterns, clinical outcomes, and patient characteristics among adults with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.
Eligibility
- Age range
- 18–115 years
- Sex
- Male
- Healthy volunteers
- No
Detailed criteria
Inclusion criteria: * Diagnosis of mCRPC between 01 January 2021 and 31 December 2025. * Male sex at index, where index is the date of initial mCRPC diagnosis. * Age 18 years at index. Exclusion criteria: • None
Location
- NovartisEast Hanover, New Jersey